KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBITDA (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed EBITDA for 11 consecutive years, with -$500000.0 as the latest value for Q4 2025.

  • Quarterly EBITDA rose 96.9% to -$500000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$55.4 million through Dec 2025, up 25.11% year-over-year, with the annual reading at -$91.1 million for FY2025, 23.24% down from the prior year.
  • EBITDA hit -$500000.0 in Q4 2025 for Fulgent Genetics, up from -$15.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $266.9 million in Q1 2021 to a low of -$151.1 million in Q4 2023.
  • Historically, EBITDA has averaged $28.4 million across 5 years, with a median of -$7.9 million in 2025.
  • Biggest five-year swings in EBITDA: soared 14045.77% in 2021 and later crashed 18990.12% in 2023.
  • Year by year, EBITDA stood at $150.9 million in 2021, then tumbled by 99.47% to $800000.0 in 2022, then plummeted by 18990.12% to -$151.1 million in 2023, then surged by 89.32% to -$16.1 million in 2024, then skyrocketed by 96.9% to -$500000.0 in 2025.
  • Business Quant data shows EBITDA for FLGT at -$500000.0 in Q4 2025, -$15.4 million in Q3 2025, and -$19.7 million in Q2 2025.